Septodont adds oraverse to its pain control offerings

March 21, 2012
Stan Goff
Issue 6

Septodont Inc. is known as a leader in dental anesthetics and related products. Septocaine is one of the most used local anesthetics in dentistry and the company has a wide offering of related pain control products including its new Septoject Evolution needles.

Septodont Inc. is known as a leader in dental anesthetics and related products. Septocaine is one of the most used local anesthetics in dentistry and the company has a wide offering of related pain control products including its new Septoject Evolution needles. Septodont’s Paul Mondock, VP Sales & Marketing, offers some additional information here including commentary about the company’s recent acquisition of OraVerse.  

“Septodont has a tremendous responsibility in being the premier dental anesthetic manufacturer worldwide,” he said. “In the USA, we have earned the distinction of having the No. 1 branded product in our industry-Septocaine.  Our entire sales and marketing team is highly trained and has a wealth of experience working with and speaking to dentists about their pain control needs.”

Mondock adds that Septodont’s goal is to be the “go to” company for questions and education, a responsibility they take very seriously.

“Although pain control was the backbone to the development of our company and is the core of our success, we have established the same standards of excellence company-wide in our development of restorative materials,” he added. “We have an excellent team of scientists working on new chemistries and formulas that have been successfully adopted into the daily standard of care in dental practices worldwide. We are not resting on our laurels. We have a well-planned future that will see tremendous growth in product offerings and programs that will enhance the dental experience for both the clinician and the patient.”

Q: Why did Septodont decide this was a good time to acquire OraVerse?  And how does this strengthen the company’s offerings in the industry?

A: Any time you have an opportunity to positively impact your core business you have to at least consider it and that was the case with OraVerse.  Simply said, this product is a great fit for Septodont.  Septodont is the global leader in pain control for the dental profession, we have an educated and experienced team of pain control experts in the field that help answer dentists’ questions, as well as provide pain control solutions to make dentists better at what they do every day.  OraVerse, combined with our unsurpassed product quality and focus on innovation, provides us with a product line platform we can build from for years to come. This soon will become the standard of care for every dental practice.  In the same way that Septocaine changed the way many dentists practice today, OraVerse will positively impact the patients’ perception of how they feel about dental pain control in the future.  While dentists are our primary customer and benefit through this unique practice building tool, it is the patient who will be the true beneficiary of OraVerse.  To learn more about this product go to oraverse.com or contact your local Septodont pain control expert.

Q: While local anesthetics have long been effective, how has the company worked on improving patient comfort/dealing with anxious patients?

A: Today’s practitioner is well versed in the proper techniques in controlling the pain associated with a dental procedure.  Septodont has spent a great deal of time and resources, working hard to educate the practitioner on injection techniques that lead to a more comfortable dental experience for the patient. We also are developing products that improve the experience by minimizing the perceived fear and discomfort with products like our unique syringes, topical anesthetics and needles.  Most recently we have launched our new Septoject Evolution needle.  This needle is designed with a scalpel tip that does not puncture the soft tissue but gently glides through tissue causing less trauma and sensation at the injection site.

Q: Does Septodont have any new product launches expected soon?

A: Septodont has made a very large commitment to scientific research and development of new products.  We have extensive R&D facilities in four of our five global manufacturing facilities, two of which are located in North America.  Our company’s vision is to bring innovative, safe and effective solutions for dentistry worldwide.  That vision drives our product development and has been demonstrated by the five exciting new products we have launched in the past year that will enhance dentists’ skills.  We have many exciting projects in the works and you will see even more innovative dental products in the coming year.